| Literature DB >> 20035983 |
E David Crawford1, Gerald L Andriole, Michael Marberger, Roger S Rittmaster.
Abstract
The landmark Prostate Cancer Prevention Trial (PCPT) generated interest in the potential health benefits and cost of reducing prostate cancer risk--specifically, the potential role of 5alpha-reductase inhibitors. However, the PCPT raised several unanswered questions, including the cause and significance of the increased incidence of high-grade tumors associated with finasteride. In the present study, we review the PCPT findings and unanswered questions, next steps in this field, and ongoing prostate cancer prevention trials addressing these unanswered questions. Particular emphasis is placed on the design of the second large-scale trial of a 5alpha-reductase inhibitor, the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. 2010 Elsevier Inc. All rights reserved.Entities:
Mesh：
Year: 2009 PMID： 20035983 DOI： 10.1016/j.urology.2009.05.099
Source DB: PubMed Journal: Urology ISSN： 0090-4295 Impact factor: 2.649